Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip's worldwide team, in this podcast version of Five Must-Know Things. 

This episode includes insights from around the biopharma world for the business week ended 12 February 2021. 

The major events this time include an analysis of big pharma’s US approvals last year, a more convenient antibody regimen for COVID-19, reconfiguring of oncology R&D at one large US firm, one Swiss major’s pipeline, and the latest in the Scrip Asks series.

These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and now on Spotify Podcasts - and also via smart speakers if one of these channels has been set up as your default podcast provider. 

Stories mentioned in this episode:

(Also see "Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020" - Scrip, 5 Feb, 2021.)

(Also see "Lilly COVID-19 Neutralizing Antibody Combo’s Reduced Infusion Time Offers Advantages For Providers" - Scrip, 10 Feb, 2021.)

(Also see "Lilly Oncology President Anne White On Loxo Success, What’s To Come" - Scrip, 9 Feb, 2021.)

(Also see "Roche Confident But Cautious On Alzheimer's Hopeful" - Scrip, 8 Feb, 2021.)

(Also see "Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease" - Scrip, 9 Feb, 2021.)


Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts